Repligen (RGEN) investor relations material

Executive summary

• Q3 revenue reached $209.3M, up 10.9% reported and 12.5% organic; growth was led by Chromatography and Proteins.

• FY2026 revenue guidance was raised to $844M–$852M, with organic growth guidance of 12%–13%; BioLife contributes from its October 6 closing date.

• BioLife expands cell therapy capabilities; improving demand and record capital equipment orders support the 2027 outlook, though equipment revenue conversion remains delayed.

Financial highlights

• Q3 adjusted operating income increased 24% to $33.3M; adjusted operating margin rose 170 bps YoY to 15.9%.

• Adjusted diluted EPS rose 15% to $0.53; adjusted net income was $29.9M versus $25.9M in Q3 2025.

• GAAP net loss was $38.4M, including a $41.2M intangible asset impairment; Q3 2025 net income was $14.9M.

• Nine-month revenue increased 12.5% to $607.7M; nine-month GAAP net loss was $25.1M versus net income of $35.6M in 2025.

Outlook and guidance

• FY2026 revenue guidance is $844M–$852M, representing 14.5%–15.5% reported growth and 12%–13% organic growth; the organic growth midpoint rose 50 bps.

• Adjusted FY2026 guidance: gross margin 53.7%–54.2%, operating income $135M–$139M, operating margin 16.0%–16.3%, and diluted EPS $2.05–$2.09.

• Guidance includes $24M of partial-quarter BioLife revenue, assumes neutral FX, and reflects ~2.5 points of inorganic growth, primarily BioLife net of Polymem.

• 2027 framework, not formal guidance: reported revenue growth of at least 25% and revenue above $1B; BioLife accretion expected to be at least $0.05.